Page 3 - CANNABIDIOL (CBD) Critical Review Report Geneva, 4-7 June 2018 World Health Organization
P. 3
Cannabidiol (CBD)
Contents
Acknowledgements .................................................................................................................. 4
Summary................................................................................................................................... 5
1. Substance identification ........................................................................................................ 6
A. International Nonproprietary Name (INN) ............................................................................ 6
B. Chemical Abstract Service (CAS) Registry Number .............................................................. 6
C. Other Chemical Names .......................................................................................................... 6
D. Trade Names .......................................................................................................................... 6
E. Street Names........................................................................................................................... 6
F. Physical Appearance.............................................................................................................. 6
G. WHO Review History ............................................................................................................. 6
2. Chemistry ............................................................................................................................... 6
A. Chemical Name ...................................................................................................................... 6
B. Chemical Structure................................................................................................................. 7
C. Stereoisomers ......................................................................................................................... 7
D. Methods and Ease of Illicit Manufacturing............................................................................ 7
E. Chemical Properties............................................................................................................... 9
F. Identification and Analysis ..................................................................................................... 9
3. Ease of Convertibility Into Controlled Substances ............................................................ 10
4. General Pharmacology........................................................................................................ 11
A. Routes of administration and dosage ................................................................................... 11
B. Pharmacokinetics ................................................................................................................. 11
C. Pharmacodynamics .............................................................................................................. 12
5. Toxicology............................................................................................................................ 13
6. Adverse Reactions in Humans ............................................................................................ 13
7. Dependence Potential .......................................................................................................... 14
A. Animal Studies ...................................................................................................................... 14
B. Human Studies...................................................................................................................... 14
8. Abuse Potential.................................................................................................................... 14
A. Animal Studies ...................................................................................................................... 14
B. Human Studies...................................................................................................................... 14
9. Therapeutic Applications and Extent of Therapeutic Use and Epidemiology of Medical
Use........................................................................................................................................ 15
10. Listing on the WHO Model List of Essential Medicines.................................................... 18
11. Marketing Authorizations (as a Medicinal Product) ......................................................... 18
12. Industrial Use ...................................................................................................................... 19
13. Non-Medical Use, Abuse and Dependence ........................................................................ 20
14. Nature and Magnitude of Public Health Problems Related to Misuse, Abuse and
Dependence.......................................................................................................................... 20
15. Licit Production, Consumption and International Trade .................................................. 20
2
